Oxidized low‐density lipoprotein antibodies/high‐density lipoprotein cholesterol ratio is linked to advanced non‐alcoholic fatty liver disease lean patients

Abstract

Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio could represent an interesting biomarker associated with NASH, hepatocellular ballooning, and liver fibrosis, in lean patients. OxLDL-ab/HDL-c could play an important role for distinguishing patients with and without NAFLD complications.

Oxidized low‐density lipoprotein in non‐alcoholic steatohepatitis

“…The indications for liver biopsy in obese and non‐obese patients can be different. In the current study, non‐obese patients with NASH or advanced fibrosis had even higher oxLDL‐ab/HDL‐C ratio than their obese counterparts . In our opinion, this finding has two possible explanations.…”

“…The lack of a robust NASH biomarker hinders drug development and makes routine management of NAFLD suboptimal. In the current study, while the oxLDL‐ab/HDL‐C ratio appeared markedly increased in non‐obese patients with NASH, the findings were based on a relatively small number of patients, and formal c‐statistics and external validation have not been performed …”

“…In this issue of the Journal , Ampuero and colleagues explore the possibility of using oxLDL‐ab as a biomarker for NAFLD/NASH . This cross‐sectional study included 72 patients with biopsy‐proven NAFLD, among whom 38 had body mass index above 30 kg/m 2 and 26 had NASH.…”

“…10 In this issue of the Journal, Ampuero and colleagues explore the possibility of using oxLDL-ab as a biomarker for NAFLD/ NASH. 11 This cross-sectional study included 72 patients with biopsy-proven NAFLD, among whom 38 had body mass index above 30 kg/m 2 and 26 had NASH. By multivariate analysis, the oxLDL-ab level was independently associated with severe steatosis, while the oxLDL-ab-to-high-density lipoprotein cholesterol (HDL-C) ratio was associated with NASH and advanced fibrosis.…”

“…In the current study, while the oxLDL-ab/HDL-C ratio appeared markedly increased in non-obese patients with NASH, the findings were based on a relatively small number of patients, and formal c-statistics and external validation have not been performed. 11 On another note, the use of NASH biomarkers to monitor patients and assess treatment response is an even bigger question. At present, most biomarker studies are of cross-sectional design.…”